HSPA8 and colorectal cancer: This is illustrated in a phase I clinical trial on the application of ascites‐derived EVs for colorectal cancer treatment, in which the abundance of major histocompatibility class I (MHC‐I) and heat shock cognate 71 kDa protein (HSC70), both known to be important for the antitumor effect, were assessed using immunoblotting (Dai et al., 2008).